GMG Launches New Graphene Water Coolant Additive for Data Centres: G FLUID(TM)

GMG launches G FLUID TM, but commercial impact depends on long-term US regulatory approval.

What the company is saying

Graphene Manufacturing Group Ltd. frames the launch of G FLUID TM as a breakthrough for data centre and industrial cooling, emphasizing its patent-pending status and graphene-based formulation. The announcement highlights product performance metrics, including a 20% increase in heat transfer rate from preliminary internal testing and up to 87% anti-microbial efficacy verified by an independent laboratory under EN 1276. Market opportunity is underscored by citing a projected US$27.2 billion market size in 2035, with a 6.1% CAGR, positioning the product as targeting a large, growing segment. Regulatory progress is presented as a key milestone, with the company disclosing an amendment application to the United States Environmental Protection Agency for manufacturing approval, expected by September 2027. The tone is optimistic and forward-looking, focusing on potential rather than current commercial outcomes. The language leans on future market size and regulatory milestones, while omitting any mention of realised sales, revenue, or profitability.

What the data suggests

Disclosed data confirms that G FLUID TM is available in 1-litre packs, used at a 1:100 concentrate ratio, and that preliminary internal testing shows a 20% increase in heat transfer at a 1% dose, resulting in 0.01% graphene by weight in solution. Independent third-party laboratory testing under EN 1276 reports up to 87% anti-microbial efficacy, but the 'up to' phrasing suggests this may not be a typical result. The only financial figures relate to the addressable market: US$15 billion in 2026, projected to US$27.2 billion in 2035, but there is no data on GMG's actual sales, revenue, or market share. No evidence is provided for realised commercial adoption, binding contracts, or customer commitments. Regulatory timelines are explicit, with EPA manufacturing approval for the US market not expected before September 2027. The data is specific on product performance but lacks any financial or operational results that would indicate current commercial traction.

Analysis

The announcement uses positive language to highlight the launch of G FLUID TM and its potential benefits, but most key claims are either forward-looking or based on preliminary/internal testing rather than realised commercial outcomes. The largest market opportunity cited is a projection for 2035, and regulatory approval for US manufacturing is not expected until late 2027, indicating a long execution distance before any material financial impact. There is no disclosure of revenue, profit, or cash flow metrics, and no evidence of immediate commercial sales or profitability. The mention of capital-intensive plant risks without corresponding near-term earnings further widens the gap between narrative and measurable progress. The data supports that a product has been developed and tested, but not that it is generating revenue or profit, nor that regulatory hurdles have been cleared.

Risk flags

• ●Regulatory risk is high, as US manufacturing approval for G FLUID TM and related products is not expected until the end of September 2027. Delays or negative outcomes from the EPA could materially impact the company's ability to access the US market.
• ●Commercialisation risk is significant, with no disclosed sales, revenue, or customer commitments for G FLUID TM. The reliance on preliminary internal testing and 'up to' performance metrics raises questions about real-world efficacy and market acceptance.
• ●Capital intensity is flagged by the mention of construction, cost-overrun, technology, and ramp-up risks associated with the Gen 2.0 Plant. These risks could lead to increased expenses or delays, especially in the absence of near-term revenue streams.
• ●Disclosure risk is present, as the announcement omits key financial data such as revenue, profit, or cash flow. This lack of transparency makes it difficult for investors to assess the company's current financial health or the immediate impact of the product launch.

Bottom line

This announcement introduces G FLUID TM as a new graphene-based additive with promising lab-tested performance, but provides no evidence of actual commercial sales, revenue, or customer uptake. The cited market opportunity is large but distant, with the most optimistic scenario relying on regulatory approval that may not arrive until late 2027. All disclosed performance data is either preliminary or framed as 'up to', and no binding agreements or financial metrics are shared. Investors should treat this as an early-stage product launch with a long runway to potential value realisation and substantial regulatory and commercialisation hurdles ahead. The most important takeaway is that near-term financial impact is unlikely, and future updates should be scrutinised for concrete evidence of sales, customer adoption, or regulatory progress.

Announcement summary

(TSXV: GMG) (OTCQX: GMGMF) Graphene Manufacturing Group Ltd. announced the launch of patent pending G FLUID TM for use as a graphene water-based additive for data centre and industrial cooling circuits to increase heat transfer and reduce microbial and bacterial growth. The cooling water treatment chemicals market is valued at US$15 billion per annum in 2026 and is expected to be valued at US$27.2 billion per annum in 2035 (with a 6.1% CAGR). The initial pack size of G FLUID TM is 1 litre, used in 1:100 concentrate additive form, where 1 litre is added into 100 litres of coolant. Preliminary internal testing showed an increased heat transfer rate of approximately 20% when G FLUID TM is dosed into demineralized water at 1%, providing 0.01% of graphene by weight in final solution. G FLUID TM provides up to 87% anti-microbial testing outcomes as tested by an independent third party laboratory under testing standard EN 1276. GMG has submitted an amendment application to the United States Environmental Protection Agency seeking approval to manufacture, in addition to sell, graphene and GMG's THERMAL-XR®, G® LUBRICANT and G®FLUID products in the United States. GMG expects an EPA approval for this amendment by the end of September 2027 and the existing Consent Order conditions are not impacted for THERMAL-XR® sales into the United States.

Disagree with this article?